Eva Wessel Stratford joined the Cancer Registry of Norway in 2019 and works as a special advisor in the Section for Administration and Research Support. One of Eva's main tasks is to coordinate the expansion of the Cancer Registry's general research biobank TREASURE-HPV and to establish an associated research registry where analysis results and information from several HPV-related projects will be stored. Eva also participates in projects within research on the elimination of cervical cancer, HPV vaccination, HPV testing and the use of new biomarkers in cervical cancer screening. Eva studied biochemical research at UMIST in Manchester and Imperial College in London, followed by a PhD in cancer genetics from King's College London.
Eva Wessel Stratford joined the Cancer Registry of Norway in 2019 and works as a special adviser in the Section for Administration and Research Support.
One of her main tasks is to coordinate the expansion of the Cancer Registry's general research biobank TREASURE-HPV and to establish an associated research registry where analysis results and information from several HPV-related projects will be stored. This will ensure the reuse of valuable research material in new research projects. The biobank material includes a number of cervical specimens, and has been collected in several research projects on cervical cancer and human papilloma virus (HPV).
Wessel Stratford also participates in projects in research on cervical cancer elimination, HPV vaccination, HPV testing and the use of new biomarkers in cervical cancer screening. She is particularly involved in the testing of a new method, so-called methylation analysis, as a triage method for HPV-positive women in a screening setting.
She has studied biochemical research at UMIST in Manchester and Imperial College in London, followed by a PhD in cancer genetics from King's College London.
She has worked more than 10 years with sarcoma research at the Institute of Cancer Research at OUS, focusing on biobanking material from virtually all sarcoma patients in Norway, establishing new models for sarcoma research and preclinical testing of potential sarcoma therapies and personal cancer medication.
She has expertise in making samples available in the biobank for research.
